Literature DB >> 9952310

Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.

A D Rodrigues1.   

Abstract

With the increased availability of human liver tissue, recombinant (cDNA-expressed) cytochrome P450 proteins (rCYPs), and knowledge of the human CYP pool (e.g. immunoquantitated levels of each CYP form in native liver microsomes), it is now possible to carry out in vitro "CYP reaction phenotyping" in an integrated manner. Reaction phenotyping allows one to identify which CYP form(s) is (are) involved in the metabolism of a given drug, using a combination of data obtained with native human liver microsomes and rCYP proteins. The following describes how one can attempt to integrate such data. A total of ten drugs are included in the analysis, represented by twelve reactions (six hydroxylations, two O-demethylations, one N-demethylation, one O-deethylation, and two sulfoxidations) that are largely catalyzed (> or =20%) by various combinations of CYPs (CYP3A4, CYP2C9, CYP1A2, and CYP2D6), and characterized by a wide range of apparent Km values (12-820 microM). Briefly, reaction rates measured with individual rCYPs are normalized with respect to the nominal specific content of the corresponding CYP in native human liver microsomes. In turn, the normalized rates for each rCYP are summed, yielding a "total normalized rate" (TNR), and the normalized rate for each rCYP is expressed as a percent of the TNR (% TNR). Finally, % TNR is related to inhibition (percent inhibition in the presence of CYP form selective chemical inhibitors; % I) and univariate regression analysis (r > or = 0.63; P < or = 0.05; N > or = 10 different livers) data obtained with native human liver microsomes. Therefore, the reaction phenotype of a drug is assigned by integrating all three data sets (r, % TNR, and % I).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952310     DOI: 10.1016/s0006-2952(98)00268-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  46 in total

1.  A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.

Authors:  Matthew G Soars; Harry V Gelboin; Kristopher W Krausz; Robert J Riley
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes.

Authors:  Xiao-mei Zhuang; Jing-ting Deng; Hua Li; Wei-li Kong; Jin-xiu Ruan; Lan Xie
Journal:  Acta Pharmacol Sin       Date:  2011-10       Impact factor: 6.150

4.  In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Kees-Jan Guijt; Sjoerd Löwenthal; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

Review 5.  The conduct of drug metabolism studies considered good practice (II): in vitro experiments.

Authors:  Lee Jia; Xiaodong Liu
Journal:  Curr Drug Metab       Date:  2007-12       Impact factor: 3.731

Review 6.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

7.  Nonadditivity in human microsomal drug metabolism revealed in a study with coumarin 152, a polyspecific cytochrome P450 substrate.

Authors:  Bikash Dangi; Nadezhda Y Davydova; Nikita E Vavilov; Victor G Zgoda; Dmitri R Davydov
Journal:  Xenobiotica       Date:  2020-07-26       Impact factor: 1.908

8.  Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice.

Authors:  Krishna C Chimalakonda; Laura P James; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Lett       Date:  2013-03

9.  Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.

Authors:  P Bonnabry; J Sievering; T Leemann; P Dayer
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.

Authors:  Yaofeng Cheng; Lifei Wang; Lisa Iacono; Donglu Zhang; Weiqi Chen; Jiachang Gong; William Griffith Humphreys; Jinping Gan
Journal:  Br J Clin Pharmacol       Date:  2017-10-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.